INTRODUCTION: Barasertib is the pro-drug of barasertib-hydroxy-quinazoline pyrazole anilide, a selective Aurora B kinase inhibitor that has demonstrated preliminary anti-AML activity in the clinical setting. PATIENTS AND METHODS: This Phase I dose-escalation study evaluated the safety and tolerability of barasertib, combined with LDAC, in patients aged 60 years or older with de novo or secondary AML. Barasertib (7-day continuous intravenous infusion) plus LDAC 20 mg (subcutaneous injection twice daily for 10 days) was administered in 28-day cycles. The MTD was defined as the highest dose at which ≤ 1 patient within a cohort of 6 experienced a dose-limiting toxicity (DLT) (clinically significant adverse event [AE] or laboratory abnormality considered related to barasertib). The MTD cohort was expanded to 12 patients. RESULTS: Twenty-two patients (median age, 71 years) received ≥ 1 treatment cycle (n = 6, 800 mg; n = 13, 1000 mg; n = 3, 1200 mg). DLTs were reported in 2 patients (both, National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 stomatitis/mucositis; 1200 mg cohort). The most common AEs were infection (73%), febrile neutropenia (59%), nausea (50%), and diarrhea (46%). Barasertib plus LDAC resulted in an overall response rate (International Working Group criteria) of 45% (n = 10/22; according to investigator opinion). CONCLUSION: The MTD of 1000 mg barasertib in combination with LDAC in older patients with AML was associated with acceptable tolerability and preliminary anti-AML activity.
INTRODUCTION:Barasertib is the pro-drug of barasertib-hydroxy-quinazoline pyrazole anilide, a selective Aurora B kinase inhibitor that has demonstrated preliminary anti-AML activity in the clinical setting. PATIENTS AND METHODS: This Phase I dose-escalation study evaluated the safety and tolerability of barasertib, combined with LDAC, in patients aged 60 years or older with de novo or secondary AML. Barasertib (7-day continuous intravenous infusion) plus LDAC 20 mg (subcutaneous injection twice daily for 10 days) was administered in 28-day cycles. The MTD was defined as the highest dose at which ≤ 1 patient within a cohort of 6 experienced a dose-limiting toxicity (DLT) (clinically significant adverse event [AE] or laboratory abnormality considered related to barasertib). The MTD cohort was expanded to 12 patients. RESULTS: Twenty-two patients (median age, 71 years) received ≥ 1 treatment cycle (n = 6, 800 mg; n = 13, 1000 mg; n = 3, 1200 mg). DLTs were reported in 2 patients (both, National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 stomatitis/mucositis; 1200 mg cohort). The most common AEs were infection (73%), febrile neutropenia (59%), nausea (50%), and diarrhea (46%). Barasertib plus LDAC resulted in an overall response rate (International Working Group criteria) of 45% (n = 10/22; according to investigator opinion). CONCLUSION: The MTD of 1000 mg barasertib in combination with LDAC in older patients with AML was associated with acceptable tolerability and preliminary anti-AML activity.
Authors: Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Adedayo Oke; Daniel Pearce; Robert W Wilkinson; Claire Crafter; Rajesh Odedra; Jamie Cavenagh; Jude Fitzgibbon; Andrew T Lister; Simon Joel; Dominique Bonnet Journal: Cancer Res Date: 2009-04-14 Impact factor: 12.701
Authors: Alan K Burnett; Donald Milligan; Archie G Prentice; Anthony H Goldstone; Mary F McMullin; Robert K Hills; Keith Wheatley Journal: Cancer Date: 2007-03-15 Impact factor: 6.860
Authors: Barbara A Helfrich; Jihye Kim; Dexiang Gao; Daniel C Chan; Zhiyong Zhang; Aik-Choon Tan; Paul A Bunn Journal: Mol Cancer Ther Date: 2016-08-05 Impact factor: 6.261
Authors: Hagop M Kantarjian; Michael W Schuster; Nitin Jain; Anjali Advani; Elias Jabbour; Erick Gamelin; Erik Rasmussen; Gloria Juan; Abraham Anderson; Vincent F Chow; Gregory Friberg; Florian D Vogl; Mikkael A Sekeres Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047
Authors: Gautam Borthakur; Herve Dombret; Philippe Schafhausen; Tim Henrik Brummendorf; Nicolas Boissel; Elias Jabbour; Mariangela Mariani; Laura Capolongo; Patrizia Carpinelli; Cristina Davite; Hagop Kantarjian; Jorge E Cortes Journal: Haematologica Date: 2015-04-17 Impact factor: 9.941
Authors: Nidal E Muvarak; Khadiza Chowdhury; Limin Xia; Carine Robert; Eun Yong Choi; Yi Cai; Marina Bellani; Ying Zou; Zeba N Singh; Vu H Duong; Tyler Rutherford; Pratik Nagaria; Søren M Bentzen; Michael M Seidman; Maria R Baer; Rena G Lapidus; Stephen B Baylin; Feyruz V Rassool Journal: Cancer Cell Date: 2016-10-10 Impact factor: 31.743